Core Viewpoint - The investment safety margin for innovative drugs has increased significantly after a round of adjustments, and the upcoming national medical insurance negotiations in the fourth quarter are expected to catalyze further value in innovative drug investments [2][3]. Group 1: Market Performance - The innovative drug sector experienced a rebound on October 31, with multiple indices rising over 3%, including a 3.71% increase in the Guozheng Hong Kong Stock Connect Innovative Drug Index [3]. - Year-to-date performance shows that several innovative drug indices have increased by over 80%, with some reaching double their values at peak [4]. - Despite a significant adjustment since mid-September, where major indices fell over 10% and some over 20%, the fundamental and policy aspects suggest a potential for continued growth [4][6]. Group 2: Fundamental Drivers - The aging population in China is a fundamental driver for the pharmaceutical sector, with projections indicating that by the end of 2024, there will be 310 million individuals aged 60 and above, accounting for 22% of the total population [5]. - Continuous R&D investment and accelerated expansion into overseas markets are identified as core engines for profit growth among innovative drug companies [5][6]. - As of October 31, 52 out of 80 innovative drug companies reported a year-on-year increase in net profit for the first three quarters, indicating a shift towards sustainable profitability [6]. Group 3: Policy Environment - The "14th Five-Year Plan" emphasizes the acceleration of health initiatives, supporting the development of innovative drugs and medical devices, which lays a solid foundation for the sector's growth over the next five years [6]. - The introduction of the "Commercial Insurance Innovative Drug Directory" in the 2025 national medical insurance negotiations is expected to broaden market opportunities for innovative drugs [6]. Group 4: Investment Opportunities - For ordinary investors, the complexity of investing in innovative drugs suggests that utilizing ETFs may be a more accessible approach [7]. - The Southern Hong Kong Stock Connect Innovative Drug ETF (159297) is highlighted as a noteworthy option, closely tracking the Guozheng Hong Kong Stock Connect Innovative Drug Index, which has been refined to exclude CXO companies, enhancing its focus on pure innovative drug firms [7][8]. - Historical performance data shows that the Guozheng Hong Kong Stock Connect Innovative Drug Index has delivered strong returns over various time frames, making it an attractive investment vehicle [8]. Group 5: Valuation Metrics - As of October 31, the TTM P/E ratio for the Guozheng Hong Kong Stock Connect Innovative Drug Index was 41.09, indicating a relatively low valuation compared to historical levels [9]. - The macroeconomic environment appears stable, with ongoing potential catalysts in the innovative drug sector, including recent breakthroughs at international conferences and favorable domestic policy developments [9].

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) has shown significant market activity, with a recent increase of 3.38% and a trading volume of 170 million yuan, indicating strong investor interest in the innovative drug sector [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) reached a new high in both scale and shares since its inception as of October 31 [1] - The ETF has experienced net inflows for 4 out of the last 5 trading days, totaling 18.9 million yuan [1] - The index it tracks, the National Certificate Hong Kong Stock Connect Innovative Drug Index, rose by 3.67%, with notable increases in component stocks such as Senhwa Biosciences (up 10.11%) and Kanglongda (up 8.80%) [1] Group 2: Policy and Industry Insights - The ongoing negotiations for the National Medical Insurance drug list are complemented by a new commercial health insurance innovative drug directory, aimed at providing new payment channels for high-value innovative drugs [1] - The CAR-T cell drug, Rukiyou Lunsai injection from WuXi AppTec, is making progress in negotiations to be included in the commercial health insurance innovative drug directory, with a listed price of 1.29 million yuan per injection [1] - Open Source Securities notes that the current innovative drugs included in both medical insurance and commercial insurance are in the early stages of volume growth, with potential for rapid revenue increases as policies continue to support innovative drugs [2] Group 3: Institutional Investment Trends - According to Guotou Securities, the proportion of all funds heavily invested in Biotech innovative drug companies has increased to 27.53%, reflecting a 2.61 percentage point rise, indicating growing institutional interest in the innovative drug sector [2] - The increasing allocation of funds to the innovative drug sector suggests a strong market recognition of its long-term development potential [2]

Market Overview - Global markets showed mixed performance, with the Hang Seng Index down 1.43% and the Shanghai Composite Index down 0.81%, while the US markets saw slight gains, particularly the Nasdaq which rose by 0.61% [1][3] - Southbound capital saw a net inflow of HKD 8.719 billion, with Xiaomi, Meituan, and 3SBio leading in net purchases, while Tencent and SMIC experienced significant net sales [3] Economic Insights - China's manufacturing PMI fell to its lowest level since 2008, indicating a further slowdown in economic activity for Q4, with expectations of policy easing from the central bank [4] - The real estate sector continues to face challenges, with a 16.3% year-on-year decline in sales for the top 100 property companies from January to October, and a further drop in second-hand housing prices [4] Industry Analysis - The CIS market is expected to grow by 6.4% in 2024, reaching USD 23 billion, driven by the adoption of automotive ADAS and emerging applications like smart glasses [4][5] - The competitive landscape in the CIS industry is becoming more concentrated, with leaders like Sony pushing technological boundaries while competitors like Samsung focus on high-resolution solutions [5] Company Performance - Amazon reported Q3 2025 revenue of USD 180.2 billion, a 13.4% year-on-year increase, with AWS revenue exceeding expectations [6] - Coinbase's Q3 2025 revenue grew by 59% year-on-year to USD 1.79 billion, driven by strong trading performance [6] - Zhongji Xuchuang achieved record quarterly revenue of RMB 10.2 billion, a 57% year-on-year increase, supported by strong demand for 800G optical modules [7]

Core Insights - The Hong Kong pharmaceutical market is experiencing a significant rebound, driven by the recent national negotiations regarding innovative drug pricing, with the Hong Kong Stock Connect Innovative Drug ETF (159570) surging over 2% and achieving a trading volume exceeding 3.2 billion CNY [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) has seen a net inflow of nearly 700 million CNY during the trading session, indicating strong investor interest [1]. - As of October 31, the ETF's latest scale has surpassed 20.3 billion CNY, leading in both scale and liquidity among its peers [1]. - The top ten constituent stocks of the ETF account for 72.47% of its weight, showcasing a concentrated investment in innovative pharmaceuticals [7]. Group 2: Company Developments - Innovative drug companies are gaining attention due to the ongoing negotiations for the 2025 National Medical Insurance Directory, which includes a new commercial health insurance innovative drug directory [3]. - Notably, CAR-T cell therapy companies are in focus, with five high-cost CAR-T therapies passing the initial review for the commercial insurance directory, potentially increasing patient access [3]. - In Q3 2025, Innovent Biologics reported a total product revenue exceeding 3.3 billion CNY, reflecting a robust year-on-year growth of approximately 40%, driven by strong performance in oncology and other therapeutic areas [6][7]. Group 3: Clinical Trials and Global Expansion - Innovent Biologics and Pfizer have initiated two global Phase III clinical trials for their PD-1/VEGF dual antibody, SSGJ-707, targeting advanced non-small cell lung cancer and metastatic colorectal cancer [6]. - The trials are expected to enroll 1,500 and 800 patients respectively, with completion dates projected for early 2029 and early 2030, indicating a strong commitment to global market entry [6]. Group 4: Industry Outlook - Analysts suggest that the ongoing policy support for innovative drugs will likely lead to rapid revenue growth for those included in the medical insurance directory, benefiting both patients and pharmaceutical companies [4]. - The innovative drug sector is expected to continue its upward trajectory, with leading companies making significant progress both domestically and internationally [4][6].

Core Viewpoint - The Hong Kong stock market's innovative pharmaceutical sector is showing resilience, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rising by 1.40% as of November 3, 2025, driven by positive developments in the industry [1]. Group 1: Market Performance - The index's performance is highlighted by significant gains in constituent stocks, including 康诺亚-B (02162) up 5.73%, 先声药业 (02096) up 5.66%, and 康方生物 (09926) up 5.29% [1]. - Other stocks such as 一脉阳光 (02522) and 平安好医生 (01833) also experienced upward movement, indicating a broader positive trend in the sector [1]. Group 2: Industry Developments - The introduction of the "Commercial Insurance Innovative Drug Directory" marks a significant policy shift, as it is the first time this mechanism has been officially included in the national discussions on medical insurance [1]. - Pfizer has initiated two global Phase III clinical trials for its PD-1/VEGF bispecific antibody SSGJ-707 (PF-08634404), targeting first-line treatment for non-small cell lung cancer and colorectal cancer, which is expected to enhance the sector's growth prospects [1]. Group 3: Future Outlook - Research indicates that the pharmaceutical and biotechnology industry is entering a new upward cycle, with accelerated overseas orders and strong upward momentum, particularly benefiting biopharmaceutical companies with robust international capabilities [1].

Summary of the Conference Call on Chinese Innovative Pharmaceuticals Industry Overview - The Chinese innovative pharmaceutical industry is transitioning from a follower to a leader, particularly in areas such as bispecific antibodies, multi-target therapies, antibody-drug conjugates (ADCs), and targeted therapies [1][4] - The industry benefits from population and domestic demand advantages, manufacturing and supply chain capabilities, and rapidly improving innovation capabilities, leading to increased global competitiveness and asset outflows [1][5] Key Insights from ESMO 2025 - At the 2025 European Society for Medical Oncology (ESMO) conference, Chinese scholars had 23 studies selected for breakthrough abstracts, with three entering the podium for oral presentations, marking a historical high [3] - Notable performances included: - Rongchang Biopharma's ADC data in urothelial carcinoma with a PFS of 13.1 months and HR of 0.36 [3][10] - Kanglin Jere's dual HER2 ADC JSK 003 showing a DCR exceeding 96% in colorectal cancer patients [3][11] - Lepu Biopharma's TFADC for pancreatic cancer achieving a PFS of 5.8 months and MOS of 13.2 months [3][11] - Other companies like Hengrui Medicine and Jinfang also showed promising results in the KRS field [3][12] Future Developments - In 2026, Kolun Biotechnology plans to release overseas data, while Bai Li Tianheng will continue to publish significant data in nasopharyngeal carcinoma and multiple phase III clinical results [9][13] - The industry is expected to see a shift from phase I and II clinical trials to phase III, indicating a positive development trend [10] Impact of Policy Reforms - Chinese pharmaceutical policy reforms have entered a deep-water zone, with high-quality growth becoming the norm. Anticipated catalysts for industry growth include ongoing business development activities and overseas data releases from late 2025 to 2026 [6] Competitive Landscape - Chinese pharmaceutical companies are gaining ground internationally, with significant advancements in innovative drug development. Companies like Hengrui, Jinfang, and others are noted for their competitive performance [5][12][14] - The U.S. faces challenges such as patent cliffs and potential business declines, necessitating acquisitions to compensate for these issues [5] Noteworthy Research Findings - Key targets discussed at ESMO included PD-1, PD-L1, HER2 family, CDK4/6, and VEGFR [7] - Data from various companies showed promising outcomes, such as: - CMAX overall OR of 68.8% and DCR of 93.8% from Aosaikang [12] - CDK246 from China Biopharma achieving an OR of 59.3% in first-line breast cancer treatment [12] Conclusion - The Chinese innovative pharmaceutical sector is poised for significant growth and international recognition, with numerous data releases expected in the coming months and throughout 2026, reflecting a shift from following to leading in the global market [13]

Group 1 - The total amount of License-out transactions in China reached $92.03 billion in the first three quarters of 2025, with the total amount exceeding $100 billion for innovative drug licensing [1] - The transaction amount between Innovent Biologics and Takeda in October could reach up to $11.4 billion, indicating strong international collaboration in the innovative drug sector [1] - Recent announcements from 3SBio and Pfizer regarding the initiation of two global Phase III clinical trials for NSCLC and CRC highlight ongoing advancements in drug development [1] Group 2 - The innovative drug industry is expected to continue its strong performance, with leading companies like Innovent Biologics and 3SBio exceeding expectations both domestically and internationally [1] - The ongoing business development (BD) efforts are expected to deepen China's participation in the global pharmaceutical supply chain, enhancing long-term value [1] - Relevant ETFs in the innovative drug industry include the Hong Kong Stock Connect Medical ETF (520510), which has a leading CXO content, and the Hang Seng Medical ETF (159892), which emphasizes innovation [2]

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology sector, with a focus on the continued investment in domestic innovative drugs by multinational corporations (MNCs) [2]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.31%, outperforming the Wind All A index (0.41%) and the CSI 300 index (-0.43%). Key sub-sectors leading the gains included vaccines (3.38%), other biological products (3.33%), and chemical preparations (3.31%). Conversely, medical consumables (-1.98%), offline pharmacies (-1.84%), and medical devices (-1.45%) experienced declines [2][7]. - MNCs are increasingly investing in domestic innovative drugs, with significant collaborations and licensing agreements being established. Notable deals include the licensing of MWN105 by Lepu Medical to Sidera Bio, and Pfizer's registration of two global Phase III clinical studies for a dual antibody from 3SBio [2][12][13]. - Flu activity is on the rise, particularly in southern provinces, with reported ILI percentages indicating an increase compared to previous weeks and years [2][12]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector rose by 1.31%, outperforming the Wind All A index and the CSI 300 index. The leading sub-sectors were vaccines, other biological products, and chemical preparations, while medical consumables, offline pharmacies, and medical devices lagged [7][8][9]. Industry News and Key Company Announcements - Significant events include the initiation of the 2025 National Medical Insurance Directory negotiations, which will include a new category for innovative drugs under commercial health insurance [12]. - Lepu Medical's subsidiary licensed its innovative weight-loss drug MWN105 to Sidera Bio, with potential milestone payments reaching up to $1.01 billion [12][13]. - Pfizer registered two Phase III clinical studies for a dual antibody targeting advanced lung cancer and colorectal cancer [12][13]. - Roche entered a global exclusive collaboration with QX031N, a dual antibody developed by Qianxin Bio, with potential milestone payments of up to $995 million [12][13].

Group 1: Economic and Market Developments - The U.S. Federal Reserve officials expressed opposition to a rate cut in December, with the probability of a rate cut dropping to about 50% [10] - The OPEC+ group decided to increase oil production by 137,000 barrels per day in December, with a pause in production increases planned for the first quarter of next year [11] - A record outflow of $7.5 billion from gold funds was reported in the week ending last Wednesday [10] Group 2: Commodity Prices - Spot gold prices fell by 0.53% to $4,003.23 per ounce, marking a third consecutive month of gains [3][7] - WTI crude oil prices rose by 0.96% to $60.66 per barrel, while Brent crude oil increased by 0.88% to $64.47 per barrel [3][7] Group 3: Stock Market Performance - U.S. stock indices saw gains, with the Dow Jones up 0.09%, S&P 500 rising by 0.26%, and Nasdaq increasing by 0.61% [3][7] - The Hong Kong Hang Seng Index fell by 1.43%, with the Hang Seng Tech Index down 2.37% [4] - A-shares in China experienced declines, with the Shanghai Composite Index down 0.81% and the Shenzhen Component down 1.14% [5][8]

Core Viewpoint - The innovative drug sector experienced a significant surge on October 31, with notable performances in both A-shares and Hong Kong stocks, driven by the initiation of the 2025 national medical insurance negotiations and the introduction of a "commercial insurance innovative drug catalog" mechanism [1][3]. Group 1: Market Performance - The A-share innovative drug ETF (562050) rose by 2.46%, while the Hong Kong innovative drug ETF (520880) surged by 5.25%, indicating high elasticity in the sector [1]. - Major stocks such as Sanofi and InnoCare Pharmaceuticals saw gains of 11% [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has shown a year-to-date increase of 108.14%, outperforming other innovative drug indices [4][5]. Group 2: Policy and Market Drivers - The introduction of the "commercial insurance innovative drug catalog" is expected to alleviate the payment pressure for high-value innovative drugs [1][3]. - The recent meeting between U.S. and Chinese leaders has reduced potential risk factors that previously suppressed the sector's performance, leading to a possible influx of capital back into the market [3]. - The ongoing earnings season, with strong performances from companies like Innovent Biologics and Hengrui Medicine, is boosting confidence in the sector [3]. Group 3: Technical Analysis - The Hong Kong innovative drug ETF (520880) has shown a significant bullish trend, breaking through key moving averages and indicating a potential reversal in market sentiment [1]. - The MACD indicator shows a notable reduction in bearish momentum, suggesting a shift towards bullish conditions [1]. Group 4: Fund Characteristics - The Hong Kong innovative drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which exclusively includes innovative drug development companies [3][4]. - The top ten holdings account for 71.63% of the index, highlighting the dominance of leading companies in the sector [4].